Author

Anthony W. Crispino

OpenAlex ID: A5113421286

Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer

2024 · Amir Goldkorn, Catherine Tangen, et al. · JAMA Network Open · 46

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

2021 · Amir Goldkorn, Catherine Tangen, et al. · Clinical Cancer Research · 34

Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.

2020 · Amir Goldkorn, Catherine Tangen, et al. · Journal of Clinical Oncology · 4

Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.

2023 · Amir Goldkorn, Catherine Tangen, et al. · Journal of Clinical Oncology · 2

Works count: 4

Citation count: 86

H-index: 3

I10-index: 2